Agilent Technologies A

Reference table

1. What it is

Agilent Technologies (NYSE: A) is a ~$37B global maker of analytical and clinical laboratory technologies — instruments, consumables, software, and services for the life-sciences, diagnostics, and applied-chemistry markets. Spun out of Hewlett-Packard in 1999, its core products are liquid and gas chromatography (LC/GC) systems, mass spectrometry (LC-MS, GC-MS, ICP-MS), spectroscopy, cell analysis, and genomics/diagnostics tools (arrays, NGS target enrichment, pathology staining). The business model is a classic razor-and-blade: instruments pull through a long, recurring tail of columns, reagents, service contracts, and software. Fiscal year ends October 31. CEO Padraig McDonnell; ~18,000 employees.

Revenue mix (FY2025 = $6.95B; note Agilent reorganized segments in FY2025):

• By operating group (FY25 as reported): the company now reports three groups — Life Sciences & Diagnostics (LDG), Agilent CrossLab (ACG) (the recurring consumables/services engine, ~$2.9B), and Applied Markets (AMG) (~$1.3B). (FMP's product tags are mid-transition — historically Life Sciences & Applied Markets ~$3.2B, Diagnostics & Genomics ~$1.65B, CrossLab ~$1.6B in FY24 — treat the exact split as approximate through the reorg.)
• By geography (FMP tag, FY25): Americas ~$2.81B · Asia-Pacific ~$2.22B · Europe ~$1.92B. Roughly balanced, but with meaningful China / Asia-Pacific exposure — a swing factor when Chinese lab capex softens.

The strategic story management keeps returning to is the "Ignite Operating System" — an internal operational-transformation and margin-expansion program — plus a steady cadence of instrument refreshes (e.g. the new 9500 ICP-MS platform) driving a replacement cycle.

2. The expert thesis — why the panel is bullish (traceable)

There is no expert coverage of Agilent in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. No independent voice in our tracked panel has published a traceable, distilled claim on this name.

That means this deep dive carries no conviction rating and cites zero claim_ids — because there are none to cite, and fabricating conviction is against the house standard. The verdict below is entirely fundamentals- and quant-driven: it rests on the reported financials, the analyst-consensus estimate path (labeled as estimates), management's own guidance (half-weighted, §9), and Synthos's own scoring model. Readers who require expert-panel corroboration should treat this as a quant screen, not a conviction call.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. (EPS figures below are non-GAAP consensus, consistent with how Agilent guides and how the Street multiples the stock.)

Synthos fair value = the base case, ~$145 (+11%), with the full $112–$172 span as the honest range. This anchor sits modestly below the Street's $154.75 consensus (we are less willing to pay up for a mid-single-digit grower without a catalyst). This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). Agilent is a quality compounder with low exponential potential:

• Forward growth: revenue CAGR FY25→FY30E ~6.2% ($6.95B → $9.37B est); non-GAAP EPS CAGR FY26→FY30E ~9.8% ($6.06 → $8.82 est), helped by buybacks and margin expansion.
• Acceleration (the 2nd derivative) is flat-to-slightly-positive, off a low base: core revenue growth guided to ~4.5–6.0% for FY26, up modestly from a soft FY24/FY25 trough — a cyclical recovery, not a structural acceleration. This is the opposite of the forward-inflecting profile Synthos hunts for in its flagship sleeve.
• Room to run: the analytical-instruments + lab-consumables TAM is large but mature and cyclical, and at ~$37B Agilent is already a scaled incumbent. A 3–5× from here would require a re-rating and a growth regime the business has not shown. Room to run is modest.
• Reinvestment runway: capex is light (~2.7% of revenue), FCF conversion is high (~$1.15B FCF), and the company returns cash via buybacks (~$425M FY25) and a growing dividend — a return-of-capital story more than a reinvest-for-hypergrowth story.

Exponential Potential: Low (3/10). Own Agilent for durable high-single-digit earnings compounding and shareholder returns, not for a fast multibagger. A small, accelerating name with these margins would score much higher; a mature ~$37B incumbent growing ~6% does not.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $6.95B, +6.7% (FY24 $6.51B; FY23 $6.83B — note FY24 was a down year, so growth is a cyclical rebound off a trough). TTM revenue ~$7.23B.
• Quarterly trajectory (recovery underway): Q1'25 $1.68B → Q2 $1.67B → Q3 $1.74B → Q4 $1.86B → Q1'26 $1.80B → Q2'26 $1.84B (+10.0% reported, +6.3% core YoY). Sequentially healthy; the trough appears behind it.
• Margins: gross 53.0% TTM, EBITDA 27.1%, GAAP operating ~21.5%, net 19.6% TTM. Management reports Q2'26 non-GAAP operating margin of 26.4%, +130 bps YoY — the "Ignite" margin story is showing up.
• Earnings: FY25 GAAP net income $1.30B, EPS $4.59 (diluted $4.57); TTM GAAP EPS ~$5.00. Non-GAAP EPS runs higher (FY26 guided $6.00–$6.10). Q2'26 GAAP EPS $1.20 (+60% YoY, aided by a low tax quarter); non-GAAP $1.49 (+14%).
• Cash flow: FY25 operating CF $1.56B, capex ~−$0.41B, FCF ~$1.15B (FCF yield ~3.4%). High-quality, cash-generative earnings (income quality ~1.03).
• Balance sheet: total debt $3.35B, cash $1.79B, net debt $1.57B, net-debt/EBITDA 0.79× — comfortably investment-grade (FMP letter rating A-). Goodwill/intangibles $4.9B (from past deals) is ~39% of assets — an acquisition-built book to keep an eye on, but not alarming.

6. Valuation — priced in or room?

Agilent is fairly-to-fully valued, not cheap. On trailing GAAP it trades 26× EPS, 5.1× sales, 19.6× EV/EBITDA, 5.2× book. On the non-GAAP basis the Street uses, forward P/E is ~22× (FY26E $6.06) → ~20× (FY27E $6.60) → ~15× (FY30E $8.82) — the multiple compresses over time if estimates hit, but you are paying ~22× today for a ~6% revenue grower. The PEG on that math is unflattering (forward PEG >2 per FMP). FMP's letter rating is A- (strong ROE/ROA scores, weaker P/E and debt-to-equity sub-scores) — a quality signal, not a value signal.

Street targets (context, not our anchor): consensus $154.75, median $156.50, high $165, low $140 — the whole Street range sits above today's $131, i.e. the sell side sees ~18% upside. Our base FV of $145 is deliberately more conservative: we won't pay a growth multiple for mid-single-digit growth absent an accelerant. Bottom line: a high-quality-at-a-full-price stock — attractive on a pullback, unremarkable here.

7. Technicals (from the tech block)

• Trend: neutral. $130.69 sits above the 50-DMA ($123.44) but right on the 200-DMA ($130.69) — the stock is at its own multi-month pivot, neither breaking out nor breaking down. MACD +2.2 (mildly positive).
• Location: −16.9% off the 52-week high ($157.20) and +18.6% off the 52-week low ($110.24) — mid-range, with a meaningful −27% max drawdown from peak on record (a reminder this is a cyclical, not a low-vol staple).
• Momentum: RSI(14) 52 — neutral, neither overbought nor oversold. No stretched-entry signal either way.
• Relative strength (the tell): A +8.5% 12-mo vs SPY +20.6% and QQQ +30.3% — a clear laggard over the past year. 3-mo +14.1% roughly matches SPY (+13.7%) but trails QQQ (+22.0%); 6-mo −5.0% vs SPY +8.4%. Persistent underperformance.
• Read: technicals are neutral-to-cautious and do not argue for urgency. The stock is at its 200-DMA pivot after a year of lagging the market — consistent with our "Watch, buy the dip" stance. A decisive hold above the 200-DMA on a good earnings print would firm the setup; a break below would reopen the low-$120s.

8. Moat & competitive position

Agilent's moat is real but narrow-to-wide, not fortress: (1) a large installed base of instruments that locks in a recurring, high-margin tail of consumables, columns, and service (the CrossLab group) — high switching costs once a lab standardizes on Agilent methods; (2) brand and regulatory validation — analytical methods are validated to specific instruments, so replacement is sticky; (3) scale in R&D and global service. The competitive frame is a rational oligopoly in analytical instruments (Agilent, Thermo Fisher, Waters, Bruker, Danaher/SCIEX, PerkinElmer/Revvity), where players compete on performance and service more than price. The binding constraints are end-market cyclicality (pharma R&D budgets, academic/government funding, China lab capex) and slow secular growth, not disruption.

Peer set (FMP tags; market cap): Waters $24.7B, Mettler-Toledo $26.4B, and adjacent healthcare names Becton Dickinson $57B, IQVIA $34.6B, ResMed $30.4B, Edwards Lifesciences $54.3B, Alcon $34.0B, Cardinal Health $56B, Haleon $43.3B, Insmed $24.2B. The truest analytical-instruments comps here are Waters and Mettler-Toledo; Agilent's ~22× forward multiple is broadly in line with that quality cohort — again, priced, not cheap.

9. Management, capital allocation & guidance

• Capital allocation: balanced and shareholder-friendly — FY25 ~$425M buybacks and ~$282M dividends (payout ~20%, yield ~0.8%), light capex (~$0.41B), and net leverage held under 0.8×. Occasional bolt-on M&A (FY24 ~$0.86B acquisitions). This is a return-of-capital + margin-expansion profile, appropriate for a mature compounder.
• Insider activity: the sampled Form 4s are routine — F-InKind tax withholdings, an award, and one small open-market sale (director Dolsten, 1,600 shares at $135.42, 2026-05-29). CEO McDonnell's activity is tax-withholding, not discretionary selling. No alarming cluster in the window.
• Management's own guidance (self-interested — half-weight): In the Q2'26 release (2026-05-27), management raised FY26 guidance: revenue $7.39B–$7.49B (up 6.3%–7.8% reported, 4.5%–6.0% core), non-GAAP operating-margin expansion ~85 bps at the midpoint, and non-GAAP EPS $6.00–$6.10 (+8¢ at the midpoint). Q3'26 guide: revenue $1.83B–$1.85B (+5.0%–6.5% reported) and non-GAAP EPS $1.48–$1.50. CEO McDonnell cited "broad-based strength across key end markets," margin gains from the Ignite Operating System, and replacement-cycle momentum. Treat as management's own book, half-weighted; it is consistent with the consensus estimate path this note uses.

10. Catalysts & what to watch

• Next earnings: 2026-08-26 (Q3'26; Street EPS $1.47, revenue ~$1.84B; management guided non-GAAP EPS $1.48–$1.50, revenue $1.83B–$1.85B). Watch core revenue growth and whether the China/pharma recovery is holding.
• Margin execution ("Ignite"): continued non-GAAP operating-margin expansion (Q2 was +130 bps YoY) is the main EPS lever given modest top-line growth.
• End-market recovery: pharma R&D budgets, academic/government funding, and especially China lab capex — the swing factors on whether core growth accelerates toward the bull case.
• Replacement cycle: uptake of new platforms (e.g. 9500 ICP-MS) as an instrument-refresh driver.
• Capital returns / M&A: pace of buybacks and any bolt-on deals.

Thesis tripwires (what would change the call): core revenue growth rolling back toward zero (renewed end-market downturn); margin expansion stalling; a large, dilutive acquisition; or a multiple that re-rates toward 25×+ with no growth acceleration (which would move us from Watch toward Avoid on valuation).

11. Key risks

• End-market cyclicality (structural): revenue tracks pharma R&D, academic/government funding, and China lab capex — FY24 was a down year, and a fresh downturn would stall the recovery. With no valuation cushion, that is the primary risk.
• Valuation / no margin of safety: ~22× forward for ~6% revenue growth leaves little room for disappointment; a de-rating toward the peer trough would hurt.
• China / geopolitics & tariffs: meaningful Asia-Pacific exposure and management's own risk factors flag tariff/trade-policy and currency swings.
• Slow secular growth: a mature instruments market caps the upside; the story is compounding, not acceleration.
• Acquisition-built book: ~$4.9B goodwill/intangibles (~39% of assets) means execution/integration and impairment risk if deals underperform.
• No expert corroboration: unlike conviction names, there is zero independent panel support in the Synthos KB — the call rests solely on fundamentals and quant.

12. Verdict, position sizing & monitoring

Watch. Agilent is a genuinely high-quality business — 53% gross margin, 21% ROE, 12.5% ROIC, ~$1.15B FCF, sub-0.8× net leverage, a sticky recurring razor-and-blade base, and a credible margin-expansion program. But it is growing revenue only ~6%, the ~22× forward multiple already prices the quality, the stock has lagged the market for a year, and there is no expert conviction and no margin of safety at $131. That combination is a textbook Watch: a name to own on weakness, not to chase here.

• Sizing: if already held, a ~2–3% quality-defensive position is reasonable; we would not initiate aggressively at this price. A pullback toward the low-$120s (near/below the 200-DMA and toward our bear zone) would improve the risk/reward materially.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $130.69.
• Single biggest risk: end-market/replacement-cycle cyclicality with no valuation cushion to absorb a miss.

Provenance & disclosures

• Traceability: 0 KB claims, breadth 0 — there is no expert coverage of Agilent in the Synthos knowledge base, so no claim_ids are cited. Fabricated conviction is structurally impossible (claim-ID reconciliation), and this note states plainly that it is fundamentals-/quant-driven.
• Data as-of: fundamentals 2026-04-30 (Q2'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
• Non-GAAP note: forward P/E and EPS-path figures use non-GAAP consensus (how Agilent guides and how the Street multiples the stock); trailing multiples use GAAP. Both bases are labeled where used.
• Management caveat: Agilent's guidance is management's own book, half-weighted by design.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").